Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology C... ( FOXA1 biomarker predicts likelihood o...)

HOME >> BIOLOGY >> TECHNOLOGY

Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation

Date:4/23/2009

FOXA1 biomarker predicts likelihood of recurrence and long-term disease-free survival of breast cancer patients; Further strengthens Company's breast cancer menu

ALISO VIEJO, Calif., April 23 /PRNewswire-FirstCall/ -- Clarient, Inc., (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it has been granted an exclusive intellectual property license from the Indiana University Research and Technology Corporation (IURTC) for the rights to commercialize the FOXA1 biomarker, which predicts the likelihood of recurrence and long-term, disease-free breast cancer survival. The licensing of this intellectual property further strengthens Clarient's deep menu of molecular tests for breast cancer and will complement the Clarient Insight(R) Dx Breast Cancer Profile, which is expected to be released soon.

The FOXA1 marker, also known as forkhead box A1, is a gene known to cause breast cancer. Recent data presented at the 2009 USCAP (United States and Canadian Academy of Pathology) meeting demonstrated that the expression of FOXA1, now known to be an estrogen receptor associated transcription factor, correlated with Oncotype Dx(R) when performed in patient samples from Indiana University. In this clinical study of 79 ER-positive, node-negative breast cancer patients, researchers found that FOXA1 expression identified the same low risk, ER-positive, node-negative patients who can be spared toxic chemotherapy (P=0.002). Researchers concluded Oncotype Dx and the FOXA1 marker can potentially be used interchangeably if further validation studies confirm t
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
2. Clarient to Commercialize Novel Breast Cancer Profile
3. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
4. Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
5. Jim Agnello to Resign as Clarient Chief Financial Officer
6. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
7. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
8. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Pharmions Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes
11. PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism

Post Your Comments:

Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology C...( FOXA1 biomarker predicts likelihood o...)